FDMT
Company Description
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.21M | 37,000 | 20.72M | 3.13M | 18.04M | 13.61M | 6.99M | 14.13M | 5.79M |
| Net Income | (140.11M) | (160.87M) | (100.84M) | (107.49M) | (71.32M) | (56.69M) | (49.31M) | (9.55M) | (11.22M) |
| EPS | -2.42 | -2.98 | -2.58 | -3.12 | -2.46 | -2.12 | -2.00 | -0.76 | -0.76 |
| Free Cash Flow | (109.08M) | (138.37M) | (78.56M) | (98.22M) | (78.24M) | (51.91M) | (39.91M) | (16.67M) | 7.66M |
| FCF / Share | -1.88 | -2.57 | -2.01 | -3.04 | -2.82 | -1.95 | -1.51 | -1.33 | 0.52 |
| Operating CF | (109.08M) | (134.59M) | (75.79M) | (86.69M) | (69.13M) | (50.91M) | (36.71M) | (16.25M) | 8.24M |
| Total Assets | 566.71M | 560.38M | 339.89M | 261.85M | 353.49M | 288.33M | 58.23M | 96.97M | 27.32M |
| Total Debt | 21.41M | 24.61M | 14.67M | 16.12M | 16.45M | 0 | 0 | 0 | 0 |
| Cash & Equiv | 60.24M | 149.34M | 249.11M | 52.35M | 153.00M | 276.73M | 49.65M | 91.76M | 23.85M |
| Book Value | 505.66M | 510.61M | 307.83M | 231.34M | 319.11M | 256.39M | (72.97M) | (27.59M) | (19.59M) |
| Return on Equity | -0.28 | -0.32 | -0.33 | -0.46 | -0.22 | -0.22 | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.05M | 85.09M | 90,000 | 15,000 | 14,000 | 1,000 | 3,000 | 5,000 | 28,000 | (19,000) | 20.20M | 239,000 |
| Net Income | (68.76M) | 19.40M | (56.88M) | (54.66M) | (47.97M) | (49.67M) | (43.84M) | (34.95M) | (32.40M) | (32.28M) | (10.26M) | (29.62M) |
| EPS | -1.01 | 0.34 | -1.01 | -0.98 | -0.86 | -0.90 | -0.79 | -0.63 | -0.66 | -0.83 | -0.24 | -0.77 |
| Free Cash Flow | (68.12M) | 27.92M | (46.41M) | (43.44M) | (48.39M) | (46.81M) | (31.17M) | (30.59M) | (29.80M) | (25.20M) | (1.58M) | (22.87M) |
| FCF / Share | -1.00 | 0.48 | -0.83 | -0.78 | -0.87 | -0.87 | -0.56 | -0.55 | -0.60 | -0.64 | -0.04 | -0.60 |
| Operating CF | (68.12M) | 28.55M | (46.50M) | (43.38M) | (47.76M) | (45.86M) | (29.39M) | (30.24M) | (29.09M) | (24.65M) | (1.17M) | (22.07M) |
| Total Assets | 512.90M | 566.71M | 423.98M | 473.64M | 515.73M | 560.38M | 604.03M | 620.12M | 629.88M | 339.89M | 361.61M | 352.50M |
| Total Debt | 20.54M | 21.41M | 22.26M | 23.08M | 23.85M | 24.61M | 24.83M | 13.66M | 14.17M | 14.67M | 15.16M | 15.63M |
| Cash & Equiv | 72.49M | 60.24M | 48.55M | 77.16M | 133.53M | 149.34M | 187.54M | 189.06M | 275.59M | 249.11M | 275.68M | 236.31M |
| Book Value | 451.84M | 505.66M | 368.98M | 420.89M | 469.72M | 510.61M | 552.95M | 588.34M | 600.56M | 307.83M | 329.93M | 325.14M |
| Return on Equity | -0.15 | 0.04 | -0.15 | -0.13 | -0.10 | -0.10 | -0.08 | -0.06 | -0.05 | -0.10 | -0.03 | -0.09 |
